Melanoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 55
• BRAF 18
• PD-L1 22
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• CTNNB1 0
• RAS 2
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 72+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· ECOG-ACRIN Cancer Research Group· Updated 6 Oct 2026

  “Slow accrual”Registry text, quoted unchanged. Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Pfizer· Updated 23 Oct 2025

  “Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Novartis Pharmaceuticals· Updated 18 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Mayo Clinic· Updated 19 Aug 2025

  “Financial issues”Registry text, quoted unchanged. Source

• Terminated

  A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

  NCT02974725· Novartis Pharmaceuticals· Updated 13 Apr 2025

  “Business reasons”Registry text, quoted unchanged. Source

• Terminated

  Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

  NCT04375527· Jonsson Comprehensive Cancer Center· Updated 4 Dec 2024

  “poor enrollment”Registry text, quoted unchanged. Source

• Terminated

  A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

  NCT05501912· ABM Therapeutics Shanghai Company Limited· Updated 29 Nov 2024

  “Adjustment of the applicant's research and development strategy”Registry text, quoted unchanged. Source

• Terminated

  Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  NCT04190628· ABM Therapeutics Corporation· Updated 21 May 2024

  “Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source

• Suspended

  T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

  NCT05756556· ImmVira Pharma Co. Ltd· Updated 1 Feb 2024

  “Change in drug development and lifecycle management and decide to suspend this study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Dabrafenib and/or Trametinib Rollover Study

  NCT03340506· Novartis Pharmaceuticals· Source

• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

  NCT04557956· National Cancer Institute (NCI)· Source

• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· ECOG-ACRIN Cancer Research Group· Source

• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Pfizer· Source

• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Cancer Research UK· Source

• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

  NCT04074096· UNICANCER· Source

• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

  NCT04417621· Novartis Pharmaceuticals· Source

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Pfizer· Source

• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

  NCT05768178· Cancer Research UK· Source

• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed During or After Prior Treatment with Anti−PD-1 Therapy

  2023-509471-17-00· Pfizer Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 21
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 46
• Metabolomics 20
• Mass Spectrometry 9
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 120
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 56
• Machine Learning 47
• Deep Learning 44
• Cohort Studies 77
• Genome-Wide Association Study 22

• Pre-treatment machine learning prediction of local failure and time to local failure after Gamma Knife radiosurgery for radioresistant brain metastases.

  J Neurooncol, Nov 2026

• Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040.

  PLoS One, Sept 2026

• Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence.

  JCO Precis Oncol, Sept 2026

• Explainable AI-Assisted Label-Free Raman Biosensing Reveals Therapy-Associated Spectral Signatures in Melanoma Tumors.

  Biosensors (Basel), Sept 2026

• A multiscale geospatial analysis integrating explainable machine learning to characterize spatial disparities in melanoma mortality associated with environmental justice and healthcare access in the contiguous United States.

  Front Public Health, Aug 2026

• Development of a novel RNA modification-based risk model to predict prognosis and immunotherapy response in melanoma using machine learning.

  J Cancer Res Clin Oncol, Aug 2026

• Automated model-based lesion tracking in CT: colorectal liver metastases as a use case for development and performance analysis.

  Eur Radiol Exp, Jul 2026

• FFixR: a machine learning framework for accurate somatic mutation calling from FFPE RNA-seq data in cancer.

  Bioinformatics, Jul 2026

• Identification of cell pyroptosis-related gene signature for prognosis in skin cutaneous melanoma.

  Comput Biol Chem, Jun 2026

• MLMarker: a machine learning framework for tissue inference and biomarker discovery.

  Genome Biol, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.